Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
137 hedge funds and large institutions have $1.04B invested in Epizyme, Inc in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 48 increasing their positions, 43 reducing their positions, and 32 closing their positions.
1,230% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $2.17M
12% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
5% less capital invested
Capital invested by funds: $1.1B → $1.04B (-$53.7M)
9% less funds holding
Funds holding: 151 → 137 (-14)
44% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$14M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$9.02M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.41M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.58M |
| 5 |
Morgan Stanley
New York
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$11.9M |
| 2 |
PC
Pier Capital
Stamford,
Connecticut
|
-$6.85M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.45M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.97M |
EPZM Hedge Fund Activity: Q4 2020 in Review
137 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2020, worth a combined $1.04B — down 4.9% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of EPZM and 18 opened new positions — a net loss of 14 holders — while 43 trimmed existing stakes and 48 added.
The largest buyer was Redmile Group, adding an estimated $14M. The largest seller was Artal Group, exiting entirely with an estimated $11.9M sold.
- 137 institutional investors held Epizyme, Inc (EPZM) as of Q4 2020, down from 151 in Q3 2020.
- Funds reported $1.04B of Epizyme, Inc stock for Q4 2020, down 4.9% quarter-over-quarter.
- 18 funds opened new Epizyme, Inc positions in Q4 2020 and 32 closed out, a net change of -14 holders.
- The largest Epizyme, Inc buyer in Q4 2020 was Redmile Group, an estimated $14M added.
- The largest Epizyme, Inc seller in Q4 2020 was Artal Group, an estimated $11.9M sold.
Based on aggregated 13F filings for Q4 2020.